BioPharma
Cell And Gene Therapy CDMO Services Market Is On...
The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected...
Articles
What’s driving the growth of the biopharma sector across...
Standfirst: The healthcare industry, particularly the life-science and biopharma sectors, across ASEAN is seeing a shift away from a reliance on overseas expertise and imported...
BioPharma
Lack of Experience Hinders CDMOs In Cell And Gene...
CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy...
BioPharma
Cell and Gene Therapy CDMO Targets North American Growth...
uBriGene, a cell & gene therapy contract development and manufacturing organization (CDMO), is expanding into the US market with the acquisition of a state-of-the-art GMP...
BioPharma
Biopharma Spectrum To Be Driven By Automation In Next...
One of the reports concerning automation in the biopharmaceutical sector has gone on to show that the market is estimated to grow at a CAGR...
BioPharma
New UK Biotech Centres To Boost Cell And Gene...
The National Health Service Blood and Transplant from the UK, which takes care of blood as well as platelet donations as well as organ, stem...
BioPharma
Emmes Launches Cell and Gene Therapy Center
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation announced the creation of a dedicated...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.